In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets
Authors:
- Simona GranataSGSimona Granata
- Gloria SantoroGSGloria Santoro
- Valentina MasolaValentina Masola
- Paola TomeiPTPaola Tomei
- Fabio SallustioFSFabio Sallustio
- Paola PontrelliPaola Pontrelli
- Matteo AccetturoMAMatteo Accetturo
- Nadia AntonucciNANadia Antonucci
- Pierluigi CarratùPierluigi Carratù
- Antonio LupoALAntonio Lupo
- Gianluigi ZazaGianluigi Zaza
Open Access
- 20 April 2018
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (4) , 1250
Abstract
The administration of Everolimus (EVE), a mTOR inhibitor used in transplantation and cancer, is often associated with adverse effects including pulmonary fibrosis. Although the underlying mechanism is not fully clarified, this condition could be in part caused by epithelial to mesenchymal transition (EMT) of airway cells. To improve our knowledge, primary bronchial epithelial cells (BE63/3) were treated with EVE (5 and 100 nM) for 24 h. EMT markers (α-SMA, vimentin, fibronectin) were measured by RT-PCR. Transepithelial resistance was measured by Millicell-ERS ohmmeter. mRNA and microRNA profiling were performed by Illumina and Agilent kit, respectively. Only high dose EVE increased EMT markers and reduced the transepithelial resistance of BE63/3. Bioinformatics showed 125 de-regulated genes that, according to enrichment analysis, were implicated in collagen synthesis/metabolism. Connective tissue growth factor (CTGF) was one of the higher up-regulated mRNA. Five nM EVE was ineffective on the pro-fibrotic machinery. Additionally, 3 miRNAs resulted hyper-expressed after 100 nM EVE and able to regulate 31 of the genes selected by the transcriptomic analysis (including CTGF). RT-PCR and western blot for MMP12 and CTGF validated high-throughput results. Our results revealed a complex biological network implicated in EVE-related pulmonary fibrosis and underlined new potential disease biomarkers and therapeutic targets.Keywords
Funding Information
- Cystic Fibrosis (CF) Research Foundation (Delegazione FFC di Torino, Lodi/Latina, Italy) (FFC#28/2014)
- Fondazione Cariverona 2015
This publication has 66 references indexed in Scilit:
- Efficacy of everolimus, a novel mTOR inhibitor, against basal‐like triple‐negative breast cancer cellsCancer Science, 2012
- Sirolimus Enhances Cyclosporine A-Induced Cytotoxicity in Human Renal Glomerular Mesangial CellsJournal of Transplantation, 2012
- Nuclear β-Catenin Is Increased in Systemic Sclerosis Pulmonary Fibrosis and Promotes Lung Fibroblast Migration and ProliferationAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- The Embryonic Transcription Cofactor LBH Is a Direct Target of the Wnt Signaling Pathway in Epithelial Development and in Aggressive Basal Subtype Breast CancersMolecular and Cellular Biology, 2010
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibitionMolecular Cancer Therapeutics, 2009
- CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1α expression in a chondrocytic cell line, HCS-2/8, under hypoxic conditionBone, 2009
- Essential Role of MMP-12 in Fas-Induced Lung FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- AU-Rich-Element-Mediated Upregulation of Translation by FXR1 and Argonaute 2Cell, 2007
- Epithelial-Mesenchymal Interactions in Pulmonary FibrosisSeminars in Respiratory and Critical Care Medicine, 2006
- Matrix metalloproteinases as modulators of inflammation and innate immunityNature Reviews Immunology, 2004